Highlights
• INOVIQ’s SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%)
• The results of a comprehensive 483-sample case-control study established that INOVIQ's SubB2M/CA15-3 blood test significantly outperformed a leading approved CA15-3 test, demonstrating an area under the curve (AUC) of 0.93 compared to 0.70
• INOVIQ is finalizing its planned breast cancer monitoring study and advancing discussions with potential partners and Key Opinion Leaders (KOL’s) for its SubB2M platform and tests
For more information, download the attached PDF.
Download this document
